Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05451303 · ClinicalTrials.gov registry record
Detection of Oral and Throat Cancers Using OralViome Cancer Testing System
A clinical trial of Oropharynx Squamous Cell Carcinoma and Oral Squamous Cell Carcinoma, sponsored by Viome.
- Recruiting
- Registry status
- 475
- Enrollment target
- 1
- Study location
NCT05451303 is a study of Oropharynx Squamous Cell Carcinoma and Oral Squamous Cell Carcinoma that is actively recruiting participants, run by Viome. The registered enrollment target is 475 participants, above the 88-participant average among 6 other Oropharynx Squamous Cell Carcinoma trials with a reported enrollment target (440% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05451303, a study of Oropharynx Squamous Cell Carcinoma and Oral Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Viome.
- RECRUITING
- Registry status
- 475 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the design, safety and efficacy of OralViome Cancer Testing system in the early detection of Oral and Throat Cancers using saliva metatranscriptomic analysis. This study will recruit only at existing clinical sites and will NOT use any additional clinical sites.
Conditions Studied
Interventions
- DEVICE OralViome Cancer Testing System
Study Locations (1)
New York
- NYMC - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 475 participants |
| Start Date | 2022-05-27 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05451303
The ClinicalTrials.gov registry entry for NCT05451303 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 475 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 88-participant average among 6 other Oropharynx Squamous Cell Carcinoma trials with a reported enrollment target (440% higher). The listed sponsor is Viome, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Oropharynx Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which OralViome Cancer Testing System is the first listed.
NCT05451303 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05451303 about?
NCT05451303 is a clinical study titled "Detection of Oral and Throat Cancers Using OralViome Cancer Testing System". To evaluate the design, safety and efficacy of OralViome Cancer Testing system in the early detection of Oral and Throat Cancers using saliva metatranscriptomic analysis. This study will recruit only at existing clinical sites and will NOT use any additional clinical sites.
What is the current status of trial NCT05451303?
This trial is currently recruiting. The enrollment target is 475 participants. The study started on 2022-05-27. Estimated completion is 2026-12.
What conditions does trial NCT05451303 study?
This clinical trial studies the following conditions: Oropharynx Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Premalignant Lesion.
What interventions are being tested in trial NCT05451303?
The interventions under investigation include: OralViome Cancer Testing System (DEVICE).
Who is sponsoring clinical trial NCT05451303?
This trial is sponsored by Viome, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05451303 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oropharynx Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
RECRUITING · Phase 2
-
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
RECRUITING · Phase 2
-
Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
RECRUITING
-
Training Swallowing Initiation During Expiration
RECRUITING · NA
-
Saliva-based Detection of CD44
COMPLETED
Explore more on PlainTrial
Oropharynx Squamous Cell Carcinoma
All registered trials for this condition
Oral Squamous Cell Carcinoma
All registered trials for this condition
New York
All trials with a study site in New York
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.